Results of positron emission tomography (PET) molecular imaging with diagnostic nuclide-labeled tracer using TGFβ-specific monoclonal antibody GC1008 as a carrier show that [89Zr]-GC1008 well penetrated recurrent high-grade gliomas, but the antibody drug GC1008 itself did not achieve the expected clinical effect in terms of efficacy (14). The gene discussed is TGFB1; the disease is glioma.